OverviewSuggest Edit

Natera (formerly known as Gene Security Network) is a genetic testing company that operates a CLIA-certified laboratory. The company offers a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; a single-gene mutation screening test to identify single-gene disorder; a carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier’s children.

TypePublic
Founded2004
HQSan Carlos, US
Websitenatera.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Dec 2019)1,039(+7%)
Job Openings143
Revenue (FY, 2019)$302.3 M(+18%)
Share Price (Sept 2020)$61.7 (+4%)
Cybersecurity ratingAMore

Key People/Management at Natera

Jonathan Sheena

Jonathan Sheena

Chief Technology Officer, Co-Founder
Matthew Rabinowitz

Matthew Rabinowitz

Executive Chairman and Co-Founder
Mike Brophy

Mike Brophy

Chief Financial Officer
Steve Chapman

Steve Chapman

Chief Executive Officer
Robert Schueren

Robert Schueren

Chief Operating Officer
Olesya Anisimova

Olesya Anisimova

Senior Vice President, Finance & Controller
Show more

Natera Office Locations

Natera has an office in San Carlos
San Carlos, US (HQ)
201 Industrial Rd suite 410
Show all (1)

Natera Financials and Metrics

Natera Revenue

Natera's revenue was reported to be $302.33 m in FY, 2019
USD

Revenue (Q2, 2020)

86.5m

Gross profit (Q2, 2020)

43.7m

Gross profit margin (Q2, 2020), %

50.6%

Net income (Q2, 2020)

(59.6m)

EBIT (Q2, 2020)

(51.7m)

Market capitalization (14-Sept-2020)

4.9b

Closing stock price (14-Sept-2020)

61.7

Cash (30-Jun-2020)

77.3m

EV

5.1b
Natera's current market capitalization is $4.9 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

217.1m210.9m257.7m302.3m

Revenue growth, %

14%(3%)22%

Cost of goods sold

135.6m139.6m166.1m

Gross profit

81.5m71.3m91.6m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

46.9m53.6m56.7m62.3m63.1m65.3m66.8m74.4m77.9m94.0m86.5m

Cost of goods sold

33.7m34.6m34.6m39.1m39.2m39.5m43.3m43.8m43.9m41.5m42.7m

Gross profit

13.2m19.1m22.0m23.3m23.9m25.8m23.5m30.5m34.0m52.5m43.7m

Gross profit Margin, %

28%36%39%37%38%40%35%41%44%56%51%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

15.3m12.6m46.4m61.9m

Accounts Receivable

13.4m8.3m62.2m53.4m

Prepaid Expenses

7.1m8.6m6.2m16.4m

Inventories

6.4m9.0m13.6m12.4m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

9.1m7.1m11.2m33.7m12.3m34.5m34.3m29.9m51.6m74.1m77.3m

Accounts Receivable

7.5m7.1m7.3m50.3m57.0m60.4m60.3m63.0m58.9m61.6m58.7m

Prepaid Expenses

7.9m5.7m6.4m5.9m7.2m6.4m5.6m5.7m14.0m15.6m15.5m

Inventories

8.2m7.4m9.2m11.9m12.3m12.2m13.7m15.2m12.5m14.2m18.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(95.8m)(136.3m)(128.2m)(124.8m)

Depreciation and Amortization

6.2m7.1m7.5m7.7m

Inventories

(2.1m)(3.1m)(4.9m)917.0k

Accounts Payable

1.3m217.0k3.8m(6.3m)
USDFY, 2016

Revenue/Employee

254.8k

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2 x
Show all financial metrics

Natera Operating Metrics

Q1, 2016Q2, 2016Q3, 2016FY, 2016Q1, 2017Q2, 2017Q3, 2017FY, 2017Q1, 2018Q2, 2018Q3, 2018FY, 2018Q1, 2019Q2, 2019Q3, 2019

Countries Covered

61 81 81

Covered Lives

200 m200 m200 m203 m195 m198 m198 m208 m200 m205 m205 m209 m209 m209 m209 m

Laboratory Distribution Partners

70 70 70 70 70 70 70 90 90 90 90 100 100 100 100

Tests

105 k209 k318 k447 k121 k247.10 k377.50 k515.20 k164.36 k327.16 k494.33 k668.60 k200.19 k394.66 k594.88 k
Show all operating metrics

Natera Acquisitions / Subsidiaries

Company NameDateDeal Size
Natera International, Inc.

Natera Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Natera Revenue Breakdown

Embed Graph

Natera revenue breakdown by business segment: 6.7% from Licensing and Other and 93.3% from Genetic Tests

Natera revenue breakdown by geographic segment: 8.1% from Europe, Middle East, India, Africa, 87.7% from United States and 4.2% from Other

Natera Online and Social Media Presence

Embed Graph

Natera News and Updates

Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer

SAN CARLOS, Calif., Sept. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program (MOLDX) has finalized a local coverage determination (LCD) to provide Medicare benefits for...

Natera to Offer $250 Million Convertible Senior Notes Due 2027

SAN CARLOS, Calif., April 13, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that it proposes to offer $250 million aggregate principal amount of convertible senior notes due 2027 (the "notes"), subject to market conditions and other factors. The notes are to be offered...

Natera Announces Preliminary First Quarter 2020 Financial Results

SAN CARLOS, Calif., April 13, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced preliminary operational and financial results for the quarter ended March 31, 2020. Natera generated total revenues of approximately $89...

Natera to Showcase Leadership in Cell-Free DNA at CEoT Conference

SAN CARLOS, Calif., March 4, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will be participating in the Cutting Edge of Transplantation (CEoT) conference taking place March 5-7, 2020 in Phoenix, Arizona. On...

Natera to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., March 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast live presentations at the Cowen and Company 40th Annual Health Care Conference in Boston on Wednesday, March 4, 2020 at...

Natera Announces Fourth Quarter and Fiscal 2019 Earnings Conference Call

SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019, after the market close on February 26, 2020. Natera...
Show more

Natera Blogs

ESMO GI Learn More

2020 ASCO recap: new format, new insights

“Although the pandemic prevented us from gathering in Chicago, it didn’t stop us from fulfilling our mission of sharing knowledge to accelerate progress for millions of people worldwide living with cancer,” said Howard A. “Skip” Burris III, MD, FACP, FASCO, president of ASCO at the time of the annu…

Employee spotlight: Himanshu Sethi, Director, Research & Development

  Tell us a little about yourself and your background. I am a self-driven and curious scientist with training in molecular cell biology, education, and public health policy. I have been with Natera for a little over four years and have over 20 years of experience in the biotech industry.   Why did …

Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas

Grows capacity to process up to three million tests annually SAN CARLOS, Calif., June 22, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the expansion of its laboratory facility in Austin, Texas, supporting greater test…

Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing

Two large-scale studies evaluating use of Signatera in colorectal cancer gain early momentum SAN CARLOS, Calif., June 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan and BESP…
Show more

Natera Frequently Asked Questions

  • When was Natera founded?

    Natera was founded in 2004.

  • Who are Natera key executives?

    Natera's key executives are Jonathan Sheena, Matthew Rabinowitz and Mike Brophy.

  • How many employees does Natera have?

    Natera has 1,039 employees.

  • What is Natera revenue?

    Latest Natera annual revenue is $302.3 m.

  • What is Natera revenue per employee?

    Latest Natera revenue per employee is $291 k.

  • Who are Natera competitors?

    Competitors of Natera include Progenity, 23andMe and Ambry Genetics.

  • Where is Natera headquarters?

    Natera headquarters is located at 201 Industrial Rd suite 410, San Carlos.

  • Where are Natera offices?

    Natera has an office in San Carlos.

  • How many offices does Natera have?

    Natera has 1 office.